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Abstract: Understanding the telomere maintenance mechanism (TMM) in immortal cancer cells
is vital for TMM-targeted therapies in clinical settings. In this study, we classified four telomere
maintenance mechanisms into telomerase, ALT, telomerase + ALT, and non-defined telomere main-
tenance mechanism (NDTMM) across 31 cancer types using 10,704 transcriptomic datasets from
The Cancer Genome Atlas. Our results demonstrated that approximately 50% of the total cohort
displayed ALT activity with high telomerase activity in most cancer types. We confirmed significant
patient prognoses according to distinct TMMs in six cancer types: adrenocortical carcinoma (ACC),
PAAD, HNSC, SARC, GBM, and metastatic cancer. Patients with metastasis had a poor prognosis
in the ALT group (p < 0.006) subjected to RAS protein signal transduction. Glioblastoma patients
had poor prognosis in NDTMM (p < 0.0043) and showed high levels of myeloid leukocyte activation.
Pancreatic adenocarcinoma (p < 0.04) and head and neck squamous cell carcinoma (p < 0.046) patients
had a good prognosis in the ALT group with high immune cell activation. Furthermore, we showed
that master transcriptional regulators might affect the selection of the TMM pathway and explained
why different telomere maintenance mechanisms exist. Furthermore, they can be used to segregate
patients and predict responders to different TMM-targeted therapeutics.
Keywords: telomere maintenance mechanism; non-defined telomere maintenance mechanism; alter-
native lengthening of telomere
1. Introduction
The telomere maintenance (TMM) mechanism is used by cancer cells to promote
immortality [1]. Recently, as the research on telomerase [2] and alternative lengthening of
telomeres [3] in human cancer is being actively conducted, interest in the role of TMM in
the immortality of tumor cells (which is one of the hallmarks of cancer) is increasing. It has
also been studied in cancer cell lines with tumors of relevant origin based on TERT isoform
expression patterns [4].
In most cancer cells, telomerase activity is maintained; however, some cancer cells,
such as telomerase-deficient cancer cells, use an alternative lengthening of the telomeres
(ALT) mechanism for their survival [5]. Telomere lengthening is mainly mediated by TERT
(telomerase) and ALT (ATRX/DAXX alteration); however, in approximately 22% of the
samples, a non-defined telomere maintenance mechanism (NDTMM) might be involved [6].
Little is known about the NDTMM, but it has been reported in several cancer types,
including glioblastoma [7], osteosarcoma [8], and metastases of cutaneous melanoma [9]. In
addition, the role of telomere homeostasis in metastatic cancer is unknown, and targeting
TMM in aggressive metastatic tumors with a poor prognosis can be a good strategy.
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Therefore, it is crucial to understand the molecular mechanisms underlying the four types
of telomere maintenance mechanisms and their impact on the survival of patients.
To study the clinical relevance of the four TMM-associated pathways, we performed
a thorough assessment of their relationship with clinical prognostic indicators in various
cancer types. We have comprehensively analyzed ALT activities across 31 cancer types in
The Cancer Genome Atlas (TCGA) [10]. In this study, we primarily focused on the distinct
molecular features related to the four TMM types and assessed their clinical relevance.
The following results were obtained: First, cancer types differ significantly in prognosis
according to the four TMM types. Second, various cancer types have different molecular
profiles depending on the type of TMM; TMM types in pan-cancer are associated with
genomic alternations [11]. Third, certain TMMs are only associated with different biological
processes. The functional diversity of telomerase indicates important differences between
these two TMM pathways (telomerase and ALT), which may prove to be essential in cancer
for the acquisition of metastatic phenotypes [12].
Therefore, our goals were to refine our understanding of the four TMM types and use
this framework to identify drug targets that can be harnessed to overcome
TMM-type-based resistance.
2. Results
2.1. Telomere Maintenance Mechanism Separated Patient Outcome
To classify the telomere maintenance mechanisms, we used TCGA RNA-sequencing
data from 31 cancer types with pooled metastatic tumor samples from 11 cancer types
(Figure 1A, Supplementary Data Table S1). Four telomere maintenance mechanisms were
defined [10] according to the TMM signature [13]. To classify the TMM subtype using tran-
scriptome data, we used a single-sample gene enrichment score for a single patient sample
(ssGSVA) [14]. Then, we split the samples into four types: telomerase, telomerase + ALT,
ALT, and NDTMM samples for each cancer type (Figure 1A). Among 10,704 samples,
47% displayed both telomerase and ALT, 27% displayed ALT, 9% telomerase, and 17%
NDTMM [6] (Figure 1B). The four TMM activities varied across the cancer types. Cholan-
giocarcinoma (CHOL) showed no telomerase activity among the 31 cancer types. We also
calculated the telomere maintenance mechanism in metastatic tumor samples from the
TCGA, with 11 cancer types. The frequency of telomere maintenance mechanism types in
metastatic tumors was similar to that of primary tumor samples (Figure 2C). In five cancer
types, namely, adrenocortical carcinoma (ACC), pancreatic adenocarcinoma (PAAD), head
and neck squamous cell carcinoma (HNSC), sarcoma (SARC), and glioblastoma multi-
forme (GBM), the four types of telomere maintenance mechanism presented significant
prognostic value (SARC: p = 7.4 × 10−3, ACC: p = 4.0 × 10−2, GBM: p = 4.5 × 10−2,
PAAD: p = 4.0 × 10−2, HNSC: p = 4.6× 10−2) (Figure 1D). GBM had a poor survival rate for
NDTMM [15], and the ALT groups of GBM showed poor survival rate. Although NDTMM
has only been reported in certain cancer types [1], our results showed that NDTMM could
function in all cancer types.
In contrast, ACC with NDTMM had a good survival rate. ACC and GBM with ALT
displayed the opposite trend regarding survival rate. Two cancer types with the telomerase
mechanism, PAAD and HNSC, had poor outcomes. In addition, high ALT levels (p = 0.04)
were associated with a better prognosis of PAAD. Overall, our analyses showed that TMM
type might distinguish patient prognosis in a single patient sample and can be used as a
prognostic marker.




Figure 1. Telomere maintenance mechanism and survival probability for 5 cancer types. (A) The percentage of the four 
types of telomere maintenance mechanisms in tumor samples; TEL: telomerase, TEL+ALT: telomerase and alternative 
lengthening of telomere, NDTMM: non defined telomere maintenance mechanism, ALT: alternative lengthening of telo-
mere. (B) Pie chart showing the frequency of four telomere maintenance mechanisms in primary tumors of 31 cancer types, 
TEL: 9%, TEL+ALT: 47%, NDTMM: 17%, and ALT: 27%. (C) Pie chart showing the frequency of the four telomere mainte-
nance mechanisms in metastatic tumors of 11 cancer types, TEL: 8%, TEL+ALT: 50%, NDTMM: 13%, and ALT: 29%. (D) 
Kaplan–Meier plots showing the overall survival rates of patients classified according to the four telomere maintenance 
mechanisms. The p-value was calculated using the log-rank test. Five cancer types (ACC, GBM, HNSC, PAAD, and SARC) 
had significantly different prognoses. ACC, adrenocortical carcinoma; GBM, glioblastoma multiforme; HNSC, head and 
neck squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; and SARC, sarcoma. 
  
Figure 1. Telomere maintenance mechanism and survival probability for 5 cancer types. (A) The percentage of the four types
of telomere maintenance mechanisms in tumor samples; TEL: telomerase, TEL+ALT: telomerase and alternative lengthening
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Figure 2. Telomere maintenance mechanism in metastasis cancer. (A) Heat map of four types of telomere maintenance 
mechanisms in metastasis cancer. TEL+ALT: telomerase and alternative lengthening of telomere, TEL: telomerase, 
Figure 2. Telomere maintenance mechanism in metastasis cancer. (A) Heat map of four types of telomere maintenance
mechanisms in metastasis cancer. TEL+ALT: telomerase and alternative lengthening of telomere, TEL: telomerase, NDTMM:
non–defined TMM (no/low activity of telomere maintenance mechanism), ALT: alternative lengthening of telomere.
(B) Kaplan–Meier plots showing the overall survival rates for the four types of TMM in metastasis cancers. (C) Enriched
biological process in ALT samples. (D) Enriched biological process in NDTMM samples. (E) Transcriptional factors and
their target genes for ALT in metastasis cancer. (F) Heat map of correlation between S phase and significant transcriptional
factors (orange: positive, blue: negative). (G) Box plot of E2F1 expression in the four TMM types. (H) Frequency of TMM
for each tumor grade.
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Next, analysis of transcriptional factor (TFs), as master regulators, indicated that
the favorable risk with NDTMM may be regulated by the transcriptional factors NFKB1,
RUNX3, SPI1, and POLR2A (FDR = 0.0001) (Figure 2E), whereas the unfavorable risk with
ALT may be regulated by SETDB1, CBX3, HCFC1, TCF7L2, and STAT1 (FDR = 0.0001) in
the “Ras protein signal transduction” pathway, including the gene RIT1 in “RET signaling”
pathway (Figure 2F). Expression of E2F1 (Figure 2G), as an hTERT repressor TF, was
significantly different between ALT (p = 6.4 × 10−5) and NDTMM. We then assessed
the frequency of pathologic tumor stage in the four distinct TMM groups. Interestingly,
NDTMM was highly associated with grade 3, but NDTMM was present in a small fraction
of grade 4 (Figure 2H). These results demonstrate that TMMs may differentially contribute
to tumor progression of metastatic cancer. Overall, TMM types in metastatic cancer have a
frequency similar to that in primary tumors, but master regulators and signaling pathways
in ALT were different from those reported in a previous study. Therefore, the type of TMM
may be a useful prognostic marker in patients with metastatic cancer.
2.2. Molecular Characteristics Based on the Four TMM Types
ATRX and DAXX gene mutations might be more generally associated with the ALT
phenotype [18], and TERT promoter mutations enhance telomerase activation [19]. We
focused on six cancer types with distinct prognoses and identified their molecular charac-
teristics in each specific TMM type.
Repair of dysfunctional telomeres by fusion propels cells into breakage–fusion–bridge
cycles, resulting in unequal distribution of genetic material into daughter cells, and, hence,
genome instability [20]. Telomere dysfunction increases mutation rates and genomic
instability [21]. Next, we analyzed the copy number variation and tumor mutation burden
profiles of 1201 primary cancer specimens and 395 metastatic cancer specimens across six
cancer types with pooled metastatic tumor samples.
ACC and SARC showed significantly higher copy number variations in the ALT group
than in the NDTMM group (Figure 3A). Interestingly, several cancer types, including
HNSC and PAAD, displayed a high tumor mutation burden (TMB) in the four TMM types.
Metastasis cancer showed a similar pattern to ACC in four TMM types. For ACC and
metastatic cancer, the patient prognosis according to TMMs was the same. We found
that high copy number variation (CNV) in ALT was associated with poor prognosis for
ACC, SARC, and metastatic cancer (Figure 2B). The five cancer types showed significantly
different mutation frequencies between ALT and NDTMM. KRAS was the most frequently
mutated gene in ALT and TP53 was frequently mutated in NDTMM for five cancer types
(Figure 3B). We confirmed a significant difference in stemness (p < 0.0007) between ALT
and NDTMM in metastatic cancer. Both telomerase and ALT activity may cause high
stemness in GBM (Figure 3C). This result suggests that in six types of cancers a specific
telomere maintenance mechanism is associated with genomic instability of copy number
variation and mutation during cellular proliferation. In particular, in the case of ALT, it
was confirmed that the prognosis was poor compared to other TMM types; ALT type was
associated with relatively high copy number variation, and this result may provide a critical
clue to the synthesis of non-canonical telomeric DNA. Together, these studies indicate that
subtelomeres are hotspots of DNA breakage and repair, and are likely to be responsible for
the generation of complex interchromosomal duplication patterns and the rapid evolution
of these genomic regions, as well as the prevalence of large CNVs near telomeres [22].
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Figure 3. Molecular characteristics of five primary cancer types and metastatic cancers. (A) Bar chart depicting the number 
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metastatic cancer). (B) Scatter plot showing the mutation frequency between ALT and NDTMM. (C) Boxplots showing 
differences in stemness enrichment score levels among the four TMM types for GBM and metastatic cancer. 
2.4. Different Biological Processes Affected Patient Prognoses of Different TMM Groups 
We confirmed different patient prognoses according to the four TMM types (Figure 
1D). We performed a gene ontology analysis to obtain functional insights into TMM types 
according to clinical outcomes. Poor outcome-related biological pathways enriched in 
ACC with ALT were related to peptide secretion, purine-containing compound metabolic 
process, mitochondrion organization, and interferon-gamma production (Figure 4A). 
Next, we analyzed the transcription factors and target gene networks. The mitochon-
drion organization, mitochondrial respiratory chain complex assembly, organelle disas-
sembly, and regulation of ketone biosynthetic processes (FDR = 0.001) were enriched in 
ACC with ALT (Figure 4B). Mitochondrial biogenesis was higher in the ALT group than 
in the telomerase group according to a previous study [23]. The vulnerability of the mito-
chondrial genome to mutations and the somatic mutations promote poor prognosis [24].  
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2.3. Different Biological Processes Affected Patient Prognoses of Different TMM Groups
We confirmed different patient prognoses according to the four TMM types (Figure 1D).
We performed a gene ontology analysis to obtain functional insights into TMM types accord-
ing to clinical outcomes. Poor outcome-related biological pathways enriched in ACC with
ALT were related to peptide secretion, purine-containing compound metabolic process,
mitochondrion organization, and interferon-gamma production (Figure 4A).
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tween peptide secretion signature genes (n = 27) and transcriptional factors (CBX3, NRF1, EP300, and NFYB) (pink: posi-
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ZBTB7A, and RXRA). (F) Gene ontology analysis of favorable risk of HNSC with ALT. (G) Heatmap of correlation matrix
between myeloid leukocyte activation (n = 45) and transcriptional factors (E2F4, NFE2, BATF, SPI1, NFIC, TFDP1, ELF1, and
FOXM1). (H) Gene ontology analysis of unfavorable risk of GBM with NDTMM. (I) Gene ontology analysis of favorable
risk GBM with ALT.
Next, we analyzed the transcription factors and target gene networks. The mito-
chondrion organization, mitochondrial respiratory chain complex assembly, organelle
disassembly, and regulation of ketone biosynthetic processes (FDR = 0.001) were enriched
in ACC with ALT (Figure 4B). Mitochondrial biogenesis was higher in the ALT group than
in the telomerase group according to a previous study [23]. The vulnerability of the mito-
chondrial genome to mutations and the somatic mutations promote poor prognosis [24].
The unfavorable risk of ACC with ALT may be determined by the transcriptional
factors CBX3, NRF1, EP300, and NFYB (FDR = 0.001) (Figure 4C). PAAD and HNSC with
ALT and favorable risk were enriched in immune-related biological pathways such as
antigen processing and myeloid leukocyte activation (FDR = 0.001) (Figure 4D,F). EP300,
HDAC2, CEBPB, HNF4G, HNF4A, ZBTB7A, and RXRA genes were correlated with anti-
gen processing-related genes for favorable risk of PAAD with ALT (Figure 4E). Myeloid
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leukocyte activation was regulated by E2F4, NFE2, BATF, SPI1, IRF4, NFIC, TFDP1, ELF1,
and FOXM1 genes in HNSC with ALT (Figure 4G). In GBM, the poor outcome related
to NDTMM and was enriched in myeloid leukocyte activation, TNF signaling pathway,
PDGFRB pathway, ROS, and RNS production in phagocytes (Figure 4H). Favorable risk for
GBM is related ALT and enriched in cell cycle, DNA replication (Figure 4I).
Overall, our analyses showed that different biological processes might affect the four
TMM types in an individual sample of a specific cancer type.
3. Discussion
The telomere maintenance mechanisms play essential role in the immortalization of
cancer cells, and tumor cell survival is mainly maintained by two mechanisms: telomerase
and alternative lengthening of telomeres. In a previous study, 22% of all TCGA cancers
did not express TERT or had mutations in ATRX or DAXX [6]. The frequency of ALT
occurrence varies by cancer types. A higher rate of ALT activation was reported in tumors
of mesenchymal origin than in carcinomas of epithelial origin. However, the reason for
this is still not clearly known [25].
Although it is known that ALT occurs frequently in sarcoma and brain tumors, ALT
also occurs not infrequently in several epithelial cancer types (adrenocortical carcinoma:
12% [26], ganglioneuroblastoma: 14% [27], neuroblastoma: 34% [28], osteosarcoma: 64% [8],
synovial sarcoma: 9% [29], breast cancer: 2% [30], astrocytoma:42% [31], glioblastoma:
28% [32], colorectal cancer: 6% [33], kidney cancer: 5% [27], liver cancer: 7% [34], lung
cancer: 1% [35], carcinoid tumor: 6% [27], PanNET: 53% [36], paraganglioma: 13% [27],
ovary cancer: 1% [27], melanoma: 7% [37], soft tissue of malignant fibrous histiocytoma:
62% [38], leiomyosarcoma: 58% [39], liposarcoma: 25% [40], gastric carcinoma: 19% [41],
MSI-H gastric carcinoma: 57% [41], non-MSI-H gastric carcinoma: 19% [41], testis cancer:
8% [27], medullary thyroid carcinoma: 28% [42], urinary bladder: 4% [27], uterus: 2% [27]).
It has been reported that about 19% of ALT gastric cancers occur in tumors with
MSI high, but it has been recently reported that about 30% of gastric cancer occur ALT
in the stem-like molecular type [43], suggesting that ALT frequency may depend on the
molecular subtypes. Pertinent to this, since the frequency of ALT activity may be different
for each molecular subtype in individual cancer types, there would be discrepancy between
observed and predicted ALT frequency according to the composition of subgroups in
population of evaluation. Thus, it might explain a difference between the previously
reported frequency of ALT activity and that predicted in this study.
Telomerase and ALT in some cancer types (glioblastoma multiforme [7], osteosarco-
mas [8], soft tissue sarcomas [44], liposarcomas [45], fibrous histyocytomas [38], peritoneal
mesothelioma [46], adrenocortical carcinoma [26], gastric carcinomas [41]) may coexist [47].
In this study, we showed that NDTMM occurs in 30 cancer types (96.77%). In ACC,
SARC, and metastatic cancer, samples with NDTMM had the best prognosis, but the
prognosis was poor in the ALT group. We confirmed that ALT in metastatic cancer is
related to the RAS protein signaling pathway.
This suggested that ALT could use different signaling pathways for each cancer type.
In the ALT groups of ACC, SARC, and metastatic cancer, poor outcome-related molec-
ular profiles were associated with significantly higher CNV. PAAD and HNSC showed
relatively good prognosis in the telomerase group, and high immune cell activation, such
as antigen-presenting cells and myeloid leukocyte activation, was confirmed in the ALT
group. This is the first study to show that two cancer types, PAAD and HNSC, have a better
prognosis in the telomerase group than in the ALT group. In addition, we confirmed that
higher TMM activation was associated with higher stemness in metastatic cancer. Alterna-
tive lengthening of telomeres is important for epidermal homeostasis and tumorigenesis in
cancer stem cells [48]. Although our study is limited to bioinformatics analysis and has
a limited number of samples depending on the type of TMM, future study is needed to
assess associated candidate pathway genes for six cancers associated with TMM types.
Int. J. Mol. Sci. 2021, 22, 11101 9 of 11
4. Materials and Methods
4.1. Telomere Maintenance Mechanism Classification
To test the telomere maintenance mechanism, we used single-sample gene variation
analysis (ssGSVA) [14] of 31 RNA-seq data from TCGA. The TCGA mRNA expression
dataset was obtained from Broad GDAC Firehose (https://gdac.broadinstitute.org/, ac-
cessed on 1 August 2020). The gene set used to evaluate TMM was the same as that used in
a previous study [13]. We performed 100,000 or more runs to increase the statistical signifi-
cance. We classified four types of TMM per cancer, and the criteria for classification was
to find the TMM with the highest relative activity among the four types and identify the
sample. TEL, relatively high telomerase activity; ALT, ALT activity; NDTMM, non-defined
telomere maintenance mechanism with no or low telomerase activity; and TEL+ALT, ALT
activity with telomerase activity.
4.2. Differential Expression Gene Analysis in Cancer Types
We performed DEG analysis for the good outcome samples compared to the poor
outcome samples, as well as the samples with NDTMM compared to the samples with ALT
in six cancer types (ACC, GBM, HNSC, PAAD, SARC, and metastatic cancer) using the
“Limma” R package [49].
4.3. Survival Probability Analysis and Gene Ontology and Correlation Analysis
The R package “survival” [50] was used to perform the overall survival analysis and
produce the Kaplan–Meier survival plots. A log-rank test was used to assess the statistical
significance (p < 0.05). Gene ontology analysis was performed using METASCAPE [51]
and DEGs (FDR < 0.05).
4.4. Transcription Factor Analysis Protein Association Network
We identified transcription factors (TFs) and target genes using the Cytoscape plug-in
iRegulon, which pairs motifs and chromatin immunoprecipitation-sequencing (ChIP-seq)
tracks to determine the TFs controlling gene networks, and the iRegulon database (version
2015.02.12) [52]. We focused on six main TMM pathways and signature gene sets [13].
Supplementary Materials: All data are available online at https://www.mdpi.com/article/10.339
0/ijms222011101/s1.
Author Contributions: J.-Y.S. conceived and designed the study. J.-Y.S. contributed to the develop-
ment of the hypotheses and analysis schemes. J.-Y.S. performed the data analyses. All the authors
contributed to the interpretation of the results. J.-Y.S. wrote, revised, and edited the manuscript.
J.-H.C. reviewed the manuscript. All authors have read and agreed to the published version of
the manuscript.
Funding: This research was supported by a grant from the KHIDI, funded by the Ministry of Health
and Welfare, Republic of Korea (HI14C1324).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Gaspar, T.B.; Sá, A.; Lopes, J.M.; Sobrinho-Simões, M.; Soares, P.; Vinagre, J. Telomere Maintenance Mechanisms in Cancer. Genes
2018, 9, 241. [CrossRef]
2. Luo, Z.; Wang, W.; Li, F.; Songyang, Z.; Feng, X.; Xin, C.; Dai, Z.; Xiong, Y. Pan-cancer analysis identifies telomerase-associated
signatures and cancer subtypes. Mol. Cancer 2019, 18, 106. [CrossRef]
3. Armendáriz-Castillo, I.; López-Cortés, A.; García-Cárdenas, J.; Guevara-Ramírez, P.; Leone, P.; Pérez-Villa, A.; Yumiceba, V.;
Zambrano, A.; Guerrero, S.; Paz-Y-Miño, C. TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT)
Related Genes. Genes 2020, 11, 834. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 11101 10 of 11
4. Subasri, M.; Shooshtari, P.; Watson, A.; Betts, D. Analysis of TERT Isoforms across TCGA, GTEx and CCLE Datasets. Cancers 2021,
13, 1853. [CrossRef] [PubMed]
5. Claude, E.; Decottignies, A. Telomere maintenance mechanisms in cancer: Telomerase, ALT or lack thereof. Curr. Opin. Genet.
Dev. 2020, 60, 1–8. [CrossRef] [PubMed]
6. Barthel, F.P.; Wei, W.; Tang, M.; Martinez-Ledesma, E.; Hu, X.; Amin, S.B.; Akdemir, K.C.; Seth, S.; Song, X.; Wang, Q.; et al.
Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat. Genet. 2017, 49, 349–357. [CrossRef]
[PubMed]
7. Hakin-Smith, V.; Jellinek, D.A.; Levy, D.; Carroll, T.; Teo, M.; Timperley, W.R.; McKay, M.J.; Reddel, R.R.; Royds, J.A. Alternative
lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003, 361, 836–838. [CrossRef]
8. Sanders, R.P.; Drissi, R.; Billups, C.A.; Daw, N.C.; Valentine, M.B.; Dome, J.S. Telomerase Expression Predicts Unfavorable
Outcome in Osteosarcoma. J. Clin. Oncol. 2004, 22, 3790–3797. [CrossRef]
9. Gagos, S.; Papaioannou, G.; Chiourea, M.; Merk-Loretti, S.; Jefford, C.-E.; Mikou, P.; Irminger-Finger, I.; Liossi, A.; Blouin,
J.-L.; Dahoun, S. Unusually stable abnormal karyotype in a highly aggressive melanoma negative for telomerase activity. Mol.
Cytogenet. 2008, 1, 20. [CrossRef]
10. Sung, J.-Y.; Lim, H.-W.; Joung, J.-G.; Park, W.-Y. Pan-Cancer Analysis of Alternative Lengthening of Telomere Activity. Cancers
2020, 12, 2207. [CrossRef]
11. Sieverling, L.; Hong, C.; Koser, S.D.; Ginsbach, P.; Kleinheinz, K.; Hutter, B.; Braun, D.M.; Cortés-Ciriano, I.; Xi, R.; Kabbe, R.; et al.
Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat. Commun. 2020, 11, 733. [CrossRef]
12. Robinson, J.N.; Schiemann, W.P. Means to the ends: The role of telomeres and telomere processing machinery in metastasis.
Biochim. Biophys. Acta 2016, 1866, 320–329. [CrossRef]
13. Nersisyan, L.; Hopp, L.; Loeffler-Wirth, H.; Galle, J.; Loeffler, M.; Arakelyan, A.; Binder, H. Telomere Length Maintenance and
Its Transcriptional Regulation in Lynch Syndrome and Sporadic Colorectal Carcinoma. Front. Oncol. 2019, 9, 1172. [CrossRef]
[PubMed]
14. Hanzelmann, S.; Castelo, R.; Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinform.
2013, 14, 7. [CrossRef]
15. Royds, J.A.; Al Nadaf, S.; Wiles, A.K.; Chen, Y.-J.; Ahn, A.; Shaw, A.; Bowie, S.; Lam, F.; Baguley, B.C.; Braithwaite, A.W.; et al. The
CDKN2A G500 Allele Is More Frequent in GBM Patients with No Defined Telomere Maintenance Mechanism Tumors and Is
Associated with Poorer Survival. PLoS ONE 2011, 6, e26737. [CrossRef] [PubMed]
16. Ehrkamp, A.; Herrmann, C.; Stoll, R.; Heumann, R. Ras and Rheb Signaling in Survival and Cell Death. Cancers 2013, 5, 639–661.
[CrossRef] [PubMed]
17. Park, J.-I.; Venteicher, A.S.; Hong, J.Y.; Choi, J.; Jun, S.; Shkreli, M.; Chang, W.; Meng, Z.; Cheung, P.; Ji, H.; et al. Telomerase
modulates Wnt signalling by association with target gene chromatin. Nature 2009, 460, 66–72. [CrossRef] [PubMed]
18. Heaphy, C.M.; de Wilde, R.F.; Jiao, Y.; Klein, A.P.; Edil, B.H.; Shi, C.; Bettegowda, C.; Rodriguez, F.J.; Eberhart, C.G.; Hebbar, S.;
et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333, 425. [CrossRef] [PubMed]
19. Min, J.; Shay, J.W. TERT Promoter Mutations Enhance Telomerase Activation by Long-Range Chromatin Interactions. Cancer
Discov. 2016, 6, 1212–1214. [CrossRef]
20. O’Sullivan, J.R.; Karlseder, J. Telomeres: Protecting chromosomes against genome instability. Nat. Rev. Mol. Cell Biol. 2010, 11,
171–181. [CrossRef]
21. Hackett, A.J.; Feldser, D.M.; Greider, C.W. Telomere dysfunction increases mutation rate and genomic instability. Cell 2001, 106,
275–286. [CrossRef]
22. Riethman, H. Human subtelomeric copy number variations. Cytogenet. Genome Res. 2008, 123, 244–252. [CrossRef]
23. Hu, J.; Hwang, S.S.; Liesa, M.; Gan, B.; Sahin, E.; Jaskelioff, M.; Ding, Z.; Ying, H.; Boutin, A.T.; Zhang, H.; et al. Antitelomerase
Therapy Provokes ALT and Mitochondrial Adaptive Mechanisms in Cancer. Cell 2012, 148, 651–663. [CrossRef]
24. Raghav, L.; Chang, Y.-H.; Hsu, Y.-C.; Li, Y.-C.; Chen, C.-Y.; Yang, T.-Y.; Chen, K.-C.; Hsu, K.-H.; Tseng, J.-S.; Chuang, C.-Y.; et al.
Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma. Cancers 2020, 12, 755. [CrossRef]
[PubMed]
25. Henson, J.; Neumann, A.A.; Yeager, T.R.; Reddel, R. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002, 21,
598–610. [CrossRef] [PubMed]
26. Else, T.; Giordano, T.J.; Hammer, G.D. Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma. J.
Clin. Endocrinol. Metab. 2008, 93, 1442–1449. [CrossRef] [PubMed]
27. Heaphy, C.M.; Subhawong, A.P.; Hong, S.-M.; Goggins, M.G.; Montgomery, E.A.; Gabrielson, E.; Netto, G.J.; Epstein, J.I.; Lotan,
T.; Westra, W.H.; et al. Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human
Cancer Subtypes. Am. J. Pathol. 2011, 179, 1608–1615. [CrossRef]
28. Dagg, R.A.; Pickett, H.A.; Neumann, A.A.; Napier, C.E.; Henson, J.; Teber, E.T.; Arthur, J.W.; Reynolds, C.P.; Murray, J.; Haber, M.;
et al. Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Rep. 2017, 19, 2544–2556. [CrossRef]
29. Henson, J.D.; Hannay, J.A.; McCarthy, S.W.; Royds, J.A.; Yeager, T.R.; Robinson, R.; Wharton, S.B.; Jellinek, D.A.; Arbuckle, S.M.;
Yoo, J.; et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening
of telomeres in sarcomas and astrocytomas. Clin. Cancer Res. 2005, 11, 217–225.
Int. J. Mol. Sci. 2021, 22, 11101 11 of 11
30. Subhawong, A.P.; Heaphy, C.M.; Argani, P.; Konishi, Y.; Kouprina, N.; Nassar, H.; Vang, R.; Meeker, A.K. The alternative
lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. Mod. Pathol. 2009, 22,
1423–1431. [CrossRef]
31. Abedalthagafi, M.; Phillips, J.J.; Kim, G.E.; Mueller, S.; Haas-Kogen, D.A.; Marshall, R.E.; Croul, S.E.; Santi, M.R.; Cheng, J.; Zhou,
S.; et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade
pediatric and adult astrocytomas: A multi-institutional study of 214 astrocytomas. Mod. Pathol. 2013, 26, 1425–1432. [CrossRef]
32. McDonald, K.L.; McDonnell, J.; Muntoni, A.; Henson, J.; Hegi, M.; von Deimling, A.; Wheeler, H.R.; Cook, R.J.; Biggs, M.T.;
Little, N.S.; et al. Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less
Aggressive Tumor Type With Longer Survival. J. Neuropathol. Exp. Neurol. 2010, 69, 729–736. [CrossRef]
33. Boardman, L.A.; Johnson, R.A.; Viker, K.B.; Hafner, K.A.; Jenkins, R.B.; Riegert-Johnson, D.L.; Smyrk, T.C.; Litzelman, K.; Seo, S.;
Gangnon, R.; et al. Correlation of Chromosomal Instability, Telomere Length and Telomere Maintenance in Microsatellite Stable
Rectal Cancer: A Molecular Subclass of Rectal Cancer. PLoS ONE 2013, 8, e80015. [CrossRef]
34. Dilley, L.R.; Greenberg, R.A. ALTernative Telomere Maintenance and Cancer. Trends Cancer 2015, 1, 145–156. [CrossRef]
35. Amorim, J.P.; Santos, G.; Vinagre, J.; Soares, P. The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype.
Genes 2016, 7, 66. [CrossRef] [PubMed]
36. Marinoni, I.; Kurrer, A.S.; Vassella, E.; Dettmer, M.; Rudolph, T.; Banz, V.; Hunger, F.; Pasquinelli, S.; Speel, E.; Perren, A.
Loss of DAXX and ATRX Are Associated With Chromosome Instability and Reduced Survival of Patients With Pancreatic
Neuroendocrine Tumors. Gastroenterology 2014, 146, 453–460.e5. [CrossRef] [PubMed]
37. Viceconte, N.; Dheur, M.-S.; Majerova, E.; Pierreux, C.E.; Baurain, J.-F.; van Baren, N.; Decottignies, A. Highly Aggressive
Metastatic Melanoma Cells Unable to Maintain Telomere Length. Cell Rep. 2017, 19, 2529–2543. [CrossRef] [PubMed]
38. Matsuo, T.; Shay, J.W.; Wright, W.E.; Hiyama, E.; Shimose, S.; Kubo, T.; Sugita, T.; Yasunaga, Y.; Ochi, M. Telomere-Maintenance
Mechanisms in Soft-Tissue Malignant Fibrous Histiocytomas. J. Bone Jt. Surg.-Am. 2009, 91, 928–937. [CrossRef]
39. Liau, J.-Y.; Tsai, J.-H.; Jeng, Y.-M.; Lee, J.-C.; Hsu, H.-H.; Yang, C.-Y. Leiomyosarcoma with Alternative Lengthening of Telomeres
Is Associated With Aggressive Histologic Features, Loss of ATRX Expression, and Poor Clinical Outcome. Am. J. Surg. Pathol.
2015, 39, 236–244. [CrossRef]
40. Costa, A.; Daidone, M.G.; Daprai, L.; Villa, R.; Cantù, S.; Pilotti, S.; Mariani, L.; Gronchi, A.; Henson, J.D.; Reddel, R.R.; et al.
Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. Cancer Res.
2006, 66, 8918–8924. [CrossRef]
41. Omori, Y.; Nakayama, F.; Li, D.; Kanemitsu, K.; Semba, S.; Ito, A.; Yokozaki, H. Alternative lengthening of telomeres frequently
occurs in mismatch repair system-deficient gastric carcinoma. Cancer Sci. 2009, 100, 413–418. [CrossRef]
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